A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors von Wagner, A.J., Kindler, H., Gelderblom, H., Schöffski, P., Bauer, S., Hohenberger, P., Kopp, H.-G., Lopez-Martin, J.A., Peeters, M., Reichardt, P., Qin, A., Nippgen, J., Ilaria, R.L., Rutkowski, P.

Volltext

Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC) von Sobrero, A, Lenz, H-J, Eng, C, Scheithauer, W, Middleton, G, Chen, W, Esser, R, Nippgen, J, Burris, H

Volltext

591P - Impact of primary tumour side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in... von Qin, S., Liu, T., Xu, J., Li, Q., Cheng, Y., Nippgen, J., Chen, W., Li, J.

Volltext

Impact of primary tumour side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the pha... von Qin, S., Liu, T., Xu, J., Li, Q., Cheng, Y., Nippgen, J., Chen, W., Li, J.

Volltext

591PImpact of primary tumour side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the... von Qin, S, Liu, T, Xu, J, Li, Q, Cheng, Y, Nippgen, J, Chen, W, Li, J

Volltext

484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC) von Sobrero, A, Lenz, H-J, Eng, C, Scheithauer, W, Middleton, G, Chen, W, Esser, R, Nippgen, J, Burris, H

Volltext

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors von Wagner, A.J, Kindler, H, Gelderblom, H, Schöffski, Patrick, Bauer, S, Hohenberger, P, Kopp, H.-G, Lopez-Martin, J.A, Peeters, M, Reichardt, P, Qin, A, Nippgen, J, Ilaria, R.L, Rutkowski, P

Volltext

Expression of Ki‐67 in squamous cell carcinoma of the penis von Berdjis, Navid, Meye, Axel, Nippgen, Johannes, Dittert, Dag, Hakenberg, Oliver, Baretton, Gustavo B., Wirth, Manfred P.

Volltext

Analyse des principales communications intéressant l'Anthropologie faites au Congrès des Américanistes (Session de Vienne, 9-14 septembre 1908) von Nippgen, J.

Volltext

La langue primitive des Lapons, d'après K.-B. Wiklund von Nippgen, J.

Volltext

Origine et époque des emprunts d'anciens mots germaniques par les langues finnoises baltiques von Nippgen, J.

Volltext

Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (... von Cervantes, A., Macarulla, T., Martinelli, E., Rodriguez-Braun, E., Ciardiello, F., Stroh, C., Nippgen, J., Baselga, J., Tabernero, J.

Volltext

Spontaneous late rupture of orthotopic detubularized ileal neobladders: report of five cases von Nippgen, Johannes B.W, Hakenberg, Oliver W, Manseck, Andreas, Wirth, Manfred P

Volltext

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and es... von Tejpar, S., Peeters, M., Humblet, Y., Vermorken, J. B., De Hertogh, G., De Roock, W., Nippgen, J., von Heydebreck, A., Stroh, C., Van Cutsem, E.

Volltext

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience von Bokemeyer, C., Bondarenko, I., Hartmann, J. T., De Braud, F. G., Volovat, C., Nippgen, J., Stroh, C., Celik, I., Koralewski, P.

Volltext

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial von Van Cutsem, E., Nowacki, M., Lang, I., Cascinu, S., Shchepotin, I., Maurel, J., Rougier, P., Cunningham, D., Nippgen, J., Köhne, C.

Volltext

Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): Preliminary safety results (CRYSTAL) von Lang, I., Zaluski, J., Changchien, C. R., Makhson, A., Pinter, T., D’Haens, G., Lim, R., Nippgen, J., Van Cutsem, E.

Volltext

Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with new... von Stupp, R., Goldbrunner, R., Neyns, B., Schlegel, U., Clement, P., Grabenbauer, G. G., Hegi, M. E., Nippgen, J., Picard, M., Weller, M.

Volltext

An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor... von Humblet, Y., Peeters, M., Bleiberg, H., Stupp, R., Sessa, C., Roth, A., Nippgen, J., Nolting, A., Stuart, P., Giaccone, G.

Volltext

Syndrome of persisting mullerian duct with first manifestation in an adult von Zastrow, S, Nippgen, J, Manseck, A, Wirth, M P

Volltext